risankizumab IV — Competitive Intelligence Brief

risankizumab IV (risankizumab IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-23 inhibitor. Area: Immunology.

phase 3 IL-23 inhibitor IL-23 p19 subunit Immunology Small molecule

Target snapshot

risankizumab IV (risankizumab IV) — AbbVie. Risankizumab is a humanized monoclonal antibody that selectively binds to and blocks the interleukin-23 (IL-23) p19 subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
risankizumab IV TARGET	risankizumab IV	AbbVie	phase 3	IL-23 inhibitor	IL-23 p19 subunit
Mirikizumab (MIR)	Mirikizumab (MIR)	Alimentiv Inc.	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Risankizumab (RISA)	Risankizumab (RISA)	Caja Costarricense de Seguro Social	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - SC	Mirikizumab - SC	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - IV	Mirikizumab - IV	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - Intravenous (IV)	Mirikizumab - Intravenous (IV)	University of North Carolina, Chapel Hill	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Ilumya Injectable Product	Ilumya Injectable Product	Psoriasis Treatment Center of Central New Jersey	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-23 inhibitor class)

1. AbbVie · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Weill Medical College of Cornell University · 1 drug in this class